secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001104659-25-052454
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Liquidia's YUTREPIA for PAH and PH-ILD, enabling commercial launch
-------------------------------------------------------------------------------

- FDA approved YUTREPIA (treprostinil) inhalation powder for PAH and PH-ILD to improve exercise ability.
- Exclusivity for United Therapeutics' Tyvaso DPI expired May 23, 2025, clearing path for YUTREPIA final approval.
- YUTREPIA uses proprietary PRINT technology for deep-lung delivery; pivotal INSPIRE study showed tolerability.
- Liquidia intends to begin commercialization immediately; ongoing litigation may delay or prevent successful commercialization.
- Company will host a webcast May 27, 2025 at 8:30 a.m. ET to discuss commercial launch preparations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925052454/0001104659-25-052454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925052454/tm2516078d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer